530985 Sigma-AldrichMICAL-2 Inhibitor II, CCG-203971 - CAS 1443437-74-8 - Calbiochem
A cell-permeable, restricted form of CCG-1423 with enhanced potency (IC₅₀ = 4.2 µM vs 16.6 µM for PC-3 cell migration), but reduced off-target toxicity.
More>> A cell-permeable, restricted form of CCG-1423 with enhanced potency (IC₅₀ = 4.2 µM vs 16.6 µM for PC-3 cell migration), but reduced off-target toxicity. Less<<Synonyms: N-(4-Chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide, CCG 203971, MLK1 Nuclear Translocation Inhibitor II
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
1443437-74-8 | C₂₃H₂₁ClN₂O₃ |
Pricing & Availability
Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.30985.0001 |
|
Glass bottle | 10 mg |
|
— |
Description | |
---|---|
Overview | A cell-permeable, bioavailable, conformationally restricted form of CCG-1423 (Cat. No. 555558) that exhibits enhanced potency (IC50 = 4.2 µM vs 16.6 µM for PC-3 cell migration), but reduced off-target toxicity (IC50 > 100 µM in PC3 cells). Selectively represses sclerodermal fibroblasts proliferation without affecting normal cells (~30 µM). Shown to be more effective in reducing MRTF/SRF-regulated gene transcriptional signaling than Y-27632 (Cat. No. 688000). Suppresses Rho/MRTF/SRF-regulated fibrotic gene expression in primary dermal fibroblasts derived from systemic sclerosis patients in a dose-dependent manner and reverses myofibroblast phenotype in TGFβ-stimulated normal dermal fibroblasts. Blocks MRTF nuclear localization by interfering with the microtubule associated monooxygenase, calponin and LIM domain containing 2 (MICAL-2), mediated regulation of intranuclear actin polymerization. Although exhibits a short in-vivo half-life (~25 min), at higher dosage effectively prevents bleomycin-induced fibrosis in C57BL/6J mice (100 mg/kg, i.p., b.i.d.). Please note that the molecular weight for this compound is batch-specific due to variable water content. |
Catalogue Number | 530985 |
Brand Family | Calbiochem® |
Synonyms | N-(4-Chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide, CCG 203971, MLK1 Nuclear Translocation Inhibitor II |
References | |
---|---|
References | Haak, A.J., et al. 2014. J. Pharmacol. Exp. Ther. 349, 480. Johnson, L.A., et al. 2014. Inflamm. Bowel Dis. 20, 154. Bell, J.L., et al. 2013. Bioorg. Med. Chem. Lett. 23, 3826. |
Product Information | |
---|---|
CAS number | 1443437-74-8 |
Form | Off-white powder |
Hill Formula | C₂₃H₂₁ClN₂O₃ |
Chemical formula | C₂₃H₂₁ClN₂O₃ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | MICAL-2 |
Purity | ≥97% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.30985.0001 | 04055977242461 |
Documentation
MICAL-2 Inhibitor II, CCG-203971 - CAS 1443437-74-8 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Haak, A.J., et al. 2014. J. Pharmacol. Exp. Ther. 349, 480. Johnson, L.A., et al. 2014. Inflamm. Bowel Dis. 20, 154. Bell, J.L., et al. 2013. Bioorg. Med. Chem. Lett. 23, 3826. |
Data Sheet | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
|